As the Belgian pharma UCB recently inked a $1.9 billion deal to buy out Zogenix and its top drug for epilepsy, the company’s former controversial opioid has now been pulled from the market, according to a Federal Register filing by the FDA on Tuesday.
Enforcement Report - Week of December 15, 2021
In its first public safety alert in six years, the Drug Enforcement Administration is warning about a dramatic increase in fake prescription drugs being sold on the black market containing a potentially lethal dose of fentanyl.
The following quote is attributed to Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research
A study undertaken in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine has shown that training people most likely to witness an opioid overdose and providing them with naloxone, a drug that reduces the effects of overdose if administered rapidly, has the potential to significantly reduce the number of deaths in these countries if scaled up nationwide.
Alvogen Pink Brook`s Generic Hydrocodone Bitartrate Receives Approval In US
Alvogen Malta`s Generic Hydrocodone bitartrate Receives Approval in the U.S
Alvogen Pharma's Generic Hydrocodone bitartrate Receives Approval in U.S
Granules Pharms's Generic Hydrocodone Bitartrate and Acetaminophen Receives Approval In US
PALATINE, Ill., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today provided an update on its development of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets using Acura’s LIMITx™ technology intended to mitigate risks associated with overdose of the hydrocodone. In conjunction with a third party formulation developer, the formulation and manufacturing process for LTX-03 has been optimized for commercial scale. Acura’s partnered commercial manufacturer has received hydrocodone quota from the Drug Enforcement Administration and is in the process of acquiring specific auxiliary equipment for the identified manufacturing process. Acura has also completed a non-clinical small animal study to identify the benefits of a reduction in peak plasma drug concentrations (Cmax) on opioid induced respiratory depression (OIRD).